Results 201 to 210 of about 91,213 (314)

A Holistic Wellness Prescription for Parkinson's Disease: Evidence‐Based Perspectives and Unmet Needs

Movement Disorders Clinical Practice, EarlyView.
Abstract Background In modern medicine the concept of wellness is often accompanied by various misconceptions arising from several factors, including a lack of clear definitions, the commercialization of wellness, and prevailing biases and stereotypes.
Indu Subramanian, Lucia Ricciardi, Anette Schrag, Silke Appel‐Cresswell, Sushma Kola, Josefa M. Domingos, Barbara A. Pickut, Nabila Dahodwala, Abdoulaye Bocoum, Cristian Falup‐Pecurariu, Gila Bronner, Gregory M. Pontone, Laurie K. Mischley, Nélida S. Garretto, Nicola Modugno, Rachel Dolhun, Tissa Wijeratne, Victoria Tull, Bradley McDaniels, K. Ray Chaudhuri, the International Parkinson, Movement Disorder Society Task Force on Wellness, Indu Subramanian, Lucia Ricciardi, Anette Schrag, Silke Appel‐Cresswell, Sushma Kola, Josefa M. Domingos, Barbara A. Pickut, Nabila Dahodwala, Abdoulaye Bocoum, Cristian Falup‐Pecurariu, Gila Bronner, Gregory M. Pontone, Laurie K. Mischley, Nélida S. Garretto, Nicola Modugno, Rachel Dolhun, Tissa Wijeratne, Victoria Tull, K. Ray Chaudhuri   +40 more
wiley   +1 more source

A One-Step Mouse Model of Parkinson's Disease Combining rAAV-α-Synuclein and Preformed Fibrils of α-Synuclein. [PDF]

Bio Protoc
Subramanya SK, Singh D, Thakur P.
europepmc   +1 more source

Single Molecule Characterization of α-Synuclein in Aggregation-Prone States [PDF]

, 2010
Adam Trexler, Elizabeth Rhoades
openalex   +1 more source

Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

Movement Disorders Clinical Practice, EarlyView.
Abstract Background α‐synuclein seeding amplification assay (α‐synuclein SAA) development as a diagnostic biomarker for Parkinson's disease (PD) has shown promising results over the past decade. However, the utility of these assays in the prediction of disease progression is unclear.
Daniel Belete, Christian Mattjie, Brook Huxford, Jonathan P. Bestwick, Alastair J. Noyce, Cristina Simonet   +5 more
wiley   +1 more source

Current Status of α-Synuclein Biomarkers and the Need for α-Synuclein PET Tracers. [PDF]

Cells
Berman SE, Siderowf AD.
europepmc   +1 more source

Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease

, 2013
Dorota Hoffman‐Zacharska, Dariusz Koziorowski, Owen A. Ross, Michał Milewski, Jarosław Poznański, Marta Jurek, Zbigniew K. Wszołek, Alexandra I. Soto‐Ortolaza, Jarosław Sławek, Piotr Janik, Zygmunt Jamrozik, Anna Potulska‐Chromik, Barbara Jasińska‐Myga, Grzegorz Opala, Anna Krygowska‐Wajs, K Czyźewski, Dennis W. Dickson, Jerzy Bal, Andrzej Friedman   +18 more
openalex   +2 more sources

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Concentration-dependent mutational scanning probes the cellular folding landscape of α-synuclein in yeast. [PDF]

Protein Sci
Noh D, Newberry RW.
europepmc   +1 more source

The regulation of synaptic function by α-synuclein [PDF]

, 2010
Serena Bellani, Vitor Sousa, Giuseppe Ronzitti, Flavia Valtorta, Jacopo Meldolesi, Evelina Chieregatti   +5 more
openalex   +1 more source

Genetic and Pathological Testing Attitudes for Parkinson's Disease in At‐Risk Relatives

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is increasingly recognized as a neurodegenerative disorder with a broad clinical spectrum and diverse biomarkers enabling early detection. α‐synuclein seed amplification assays (SAA) and genetic testing now allow identification of PD pathology in asymptomatic individuals.
Tal Weil, Anat Mirelman, Roy N. Alcalay, Nurit Omer, Penina Ponger, Avner Thaler   +5 more
wiley   +1 more source